Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Investigation of the T cell responses against monkeypox virus will be led by Prof. Tao Dong at the CAMS-Oxford Institute and MRC Human Immunology Unit.

Illustration of Monkeypox virus. © Shutterstock/Dotted Yeti

[This article was originally published on the CAMS-Oxford Institute Website]


The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium working together to develop better diagnostic tests, identify potential therapies and study vaccine effectiveness. Bringing together 25 leading researchers and scientists from 12 institutions across the UK, the consortium has received £2 million from the Biotechnology and Biosciences Research Council (BBSRC) and the Medial Research Council (MRC), both part of UK Research and Innovation (UKRI) 

Human monkeypox infection was first identified in 1970 in the Democratic Republic of the Congo. Since then, there have been numerous outbreaks within Africa where it is endemic. In May 2022, multiple cases of monkeypox were identified in several non-endemic countries. Since May, in the UK, there have been more than 3,400 confirmed cases and internationally the WHO reports that it has now spread to 50 countries and territories.  

Monkeypox virus (MPXV) is transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets, and contaminated materials such as bedding. A member of the Orthopoxvirus genus in the family Poxviridae, monkeypox is closely related to the eradicated smallpox virus. While evidence suggests that smallpox vaccination can offer protection against monkeypox, the level of this cross-reactivity is currently unclear.  

The consortium will be led by the Pirbright Institute and the MRC-University of Glasgow Centre for Virus Research, but researchers from across University of Oxford will play a key role.  

Professor Miles Carroll’s group, based at the Pandemic Sciences Institute and the Wellcome Centre for Human Genetics, will be working with consortium colleagues on the development of a lateral flow device (LFD) for the rapid point of care diagnosis of MPXV. As MPXV infection can be confused with other common diseases, a reliable rapid diagnostic device would greatly benefit the public health response.  

Professor Tao Dong’s group will lead in the understanding of T cell responses to the virus. T cells are an integral part of the immune response to viral infections and required for clearance of the virus, as well as providing long-lasting protection through the generation of memory cells. Prof. Dong and her team, based at both the CAMS-Oxford Institute and MRC Human Immunology Unit at the MRC WIMM, will work to understand the cross-reactivity of existing T cells elicited in response to the smallpox vaccine against monkeypox infection, as well as characterising the T cell responses elicited by monkeypox infection.  

Understanding of immune responses to infection and vaccination are critical, especially characterisation of immune correlates for protection, which will increase scientific knowledge and could inform on vaccine policy going forward. - Professor Tao Dong

Read more about the consortium here.